



CooperVision Reinforces Myopia Management Leadership with Key Infrastructure, Product, and Advocacy Investments

Jennifer Lambert Named Vice President, Myopia Management & Cornea Care

ROCHESTER, N.Y., February 10, 2025—CooperVision today announced a series of investments designed to reinforce its worldwide leadership in myopia management, including actions to further bolster commercial infrastructure, pipeline growth, clinical study sponsorship, and advocacy support.

“For more than a decade, CooperVision has been changing people’s lives through myopia management, spearheading how the category has evolved in partnership with top eye care professionals, educators, and industry associations. While our range of optical interventions is unrivaled, we know there is considerable work still to be done by removing barriers, accelerating clinical adoption, and affirming myopia management as standard of care for countless children,” said Debbie Olive, CooperVision’s Chief Commercial Officer.

To provide even more dedicated support to combat the global myopia epidemic, CooperVision has elevated the myopia management group within its global commercial structure, creating the role of Vice President, Myopia Management & Cornea Care. Jennifer Lambert, who has spent the past four years as Senior Director, Global Myopia Management, has been appointed to this leadership role. The company is also adding managerial roles specific to customer engagement and new product market development, collectively designed to transform the myopia category for long-term success.

In parallel, the organization has revealed that a series of new research and development projects are underway, including investigations of novel optical designs, novel treatments, and foundational concepts relating to myopia’s onset and progression. Among these are a multi-site clinical study for a next-generation soft contact lens for myopia control. This builds on the widely prescribed MiSight® 1 day contact lens, the first and only FDA-approved soft contact lens proven to help slow the progression of myopia in children aged 8-12 at the initiation of treatment.*^{† 1}

After extensively publishing data from the world’s longest-running soft contact lens study among children with MiSight® 1 day², led by CooperVision’s internal research team, the company is now broadening its efforts to explore the economics of myopia and its treatment. Collaborating with

Manchester University's School of Optometry and Centre for Health Economics, the company has funded a PhD position for the program, working with Professor Philip Morgan and Senior Lecturer Dr. Carole Maldonado-Codina. Preliminary reporting is anticipated to begin next year.

CooperVision has also sustained its substantial financial support for myopia management advocacy initiatives around the planet, such as its pioneering partnership with the World Council of Optometry to develop and advance myopia management as standard of care, its Myopia Collective program with the American Optometric Association, and myopia management education for the academic community via the International Association of Contact Lens Educators (IACLE). It also sponsors ongoing efforts from the International Myopia Institute, the World Society of Paediatric Ophthalmology and Strabismus, and the International Agency for the Prevention of Blindness.

“We are fortunate to act from positions of strength in our science, our portfolio, and our customer relationships—all of which point us toward continuing to extend our voice and expand our leadership. Not only are a generation of children today depending on the work we are doing in partnership with the optometry and ophthalmology professions, but also millions of children in the decades ahead whose lives may be changed for the better through our innovation and efforts,” said Lambert.



Jennifer Lambert, Vice President, Myopia Management & Cornea Care, CooperVision

** Compared to a single vision 1 day lens over a 3 year period.*

[†] *Regulatory indications of and access to interventions for slowing myopia progression vary by country. CooperVision does not endorse off-label prescribing.*

References

^[1] Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. *Optom Vis Sci.* 2019; 96(8):556-567.

² CVI Data on File, 2024. Technical Memo – Summary of MiSight® 1 day MIST-401/402 Trials and Ongoing Internal and External International Studies.

#

About CooperVision

CooperVision, a division of CooperCompanies (Nasdaq:COO), is one of the world's leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.

About CooperCompanies

CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies has a workforce of more than 16,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.

Forward-Looking Statements

This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995 including, among others, statements regarding a product launch and features and technologies that may impact demand for new products. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Among the factors that could cause actual results and future actions to differ materially from those described in forward-looking statements are risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new products; risks relating to research and development, regulatory requirements, clinical studies, sales, marketing, and distribution plans and capabilities; potential product performance and quality issues; intellectual property risks; competition; and other factors described in CooperCompanies' Securities and Exchange Commission filings, including the "Business", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in Cooper's Annual Report on Form 10-K for the fiscal year ended October 31, 2023, as such Risk Factors may be updated in annual and quarterly filings. CooperCompanies cautions investors that forward-looking statements reflect the company's analysis only on their stated date. CooperCompanies disclaims any intent to update them except as required by law.

Media Contact

Mike McDougall, APR, Fellow PRSA, FAAO

McDougall Communications for CooperVision

mike@mcdougallpr.com or +1.585.545.1815